cases (n = 76) and controls (n = 151). For polymorphism rs1298865, there was no significant difference in allele or genotype frequencies (odds ratio (OR) = 1.33; 95% confidence intervals (CIs) = 0.76-2.34 and OR = 0.72 (95% CIs = 0.33-1.59) for the C and T alleles, respectively). Similarly, at rs2306987 allele and genotype frequencies did not significantly differ between case and control individuals (OR = 1.10 (95% CIs = 0.63-1.92) and OR = 0.46 (95% CIs = 0.20-1.08)) for the T and A alleles, respectively. However, consistent with Blair et al.
were undertaken. An affected status equated to a diagnosis of either BPI or BPII. From 91 pedigrees, including 36 nuclear families, 15 families were informative. Using any genetic model, there was no significant evidence of transmission disequilibrium at either locus, consistent with the UK trios in Blair et al. 1 Using the program COCAPHASE (v2.404), 9 we corroborated Blair et al.'s 1 findings of high linkage disequilibrium between the SNPs (cases: r 2 = 0.74; controls: r 2 = 0.79) and that the two common haplotypes (TA and CT) account for > 90% of the haplotype diversity in this region. However, we did not find a significant difference in haplotype frequencies between cases and controls.
In our attempts to replicate the findings of Blair et al. 1 using similar ascertainment and statistical analysis methods, we did not find support for the involvement of two FAT polymorphisms in the occurrence of BPAD. Further investigation of this proposed association is warranted within other samples to ascertain its reliability.
A polymorphism linked to bipolar affective disorder does not alter the CRE activity of constitutively activated trace amine receptor 4 Altered levels of trace amines have been observed in neuropsychiatric disorders such as schizophrenia and Letters to the Editor bipolar affective disorder (BPAD) and therefore are of particular interest in this field. 1 So far two G-protein coupled receptors (GPCR) that bind trace amines have been identified, which has led to the name 'trace amine receptors' (TA) being applied to an extended receptor subfamily with multiple members, and several pseudogenes, in both humans and rodents. 2 The endogenous ligands for the remaining TA family members are still not known; therefore, they are considered orphan GPCRs. 3 Several studies discuss a potential association of the human trace amine receptor 4 (TA4, also known as TRAR4 or TAAR6) to BPAD and schizophrenia. [4] [5] [6] [7] [8] These observations make TA4 a potential target for neuropsychiatric disorders. Recently, a study was published in this journal linking a polymorphism of TA4 to BPAD. Since the frequency of the risk allele G is indicated with 89-93%, 4 ,5 the allele A of TA4 could rather be termed as protective against BPAD. The polymorphism in allele G versus allele A leads to the amino-acid exchange V265I in the sixth transmembrane domain of TA4. 4 Here, we address the functional effect of this polymorphism on a molecular basis.
The generation of constitutively active receptors (CAMs) by mutagenesis has been shown to enable the study of receptor function in the absence of knowledge of the physiological ligand. We applied this approach to TA4. Both alleles of the human TA4 gene were cloned into pcDNA3 and pSecTag2 plasmids and their expression in HEK293 cells was confirmed using reverse transcriptase-PCR and immunocytochemistry, as described previously. 9 To generate a CAM variant of TA4, mutations leading to an amino-acid exchange R130D were introduced into the so-called DRY-motif, which is known to promote constitutive activity in GPCRs. 10 The activity of this mutant TA4 CAM , transfected transiently into HEK293 cells, was compared to the activity of wild-type TA4 using PathwayFinder-GeneArrays (SuperArray Bioscience; HS-008 and HS-028). Replicates of this experiment indicated the increased expression of several genes with the cAMP resp. element (CRE) enhancer sequence in cells transfected with TA4 CAM compared to wild-type TA4 (data not shown).
Based on this result, the activity of TA4/TA4 CAM was evaluated by measuring the phosphorylated CREB transcription factor in cell extracts. Therefore, extracts of HEK293-cells, transiently or stably transfected with the TA4 variants with the polymorphism or CAM, were blotted and the bands corresponding to phospho-CREB protein were quantified (Invitrogen (Carlsbad, CA, USA) NuPAGE system; Rockland antipCREB antibody 600-401-270). The result showed a À5 M forskolin were used as positive control. TA4 CAM shows a significant increase (*P < 0.05) of phosphorylated CREB compared to the TA4 (both allele G). (c) Response ratio in the LyticBlazer gene reporter system after 72 h expression of HEK293-CREbla cells transfected with either the appropriate TA4 plasmids or the bla reporter gene with SV40 promoter as a positive control. In either allele, TA4 CAM shows a significant signal increase compared with TA4 (*P < 0.05; **P < 0.01), whereas the difference between TA4 alleles is not significant. SV40, simian virus 40; TA, trace amine receptors.
significantly increased activation of CREB protein in cells expressing TA4 CAM compared to TA4 (Figures 1a  and b ; P < 0.05). An alternative attempt for evaluating the activity of the CRE transduction pathway was performed by using a gene reporter system with a CRE promoter (Invitrogen LyticBlazer with HEK293-CREbla cells). The cells expressing TA4 CAM of either allele showed a significant increase in the response ratio (Figure 1c ; P < 0.01 respectively P < 0.05), whereas there was no significant difference between the two alleles of TA4.
Our approach shows that CAM receptors can be used to analyze the effect of potential disease mutations on orphan receptor activity without knowledge of the endogenous ligand, where otherwise inferences can only be made on basis of the sequence differences revealed by linkage studies. These three different approaches confirm that TA4 R130D is a CAM GPCR in vivo and is likely to activate the CREB pathway in endogenous cells, comparably to TA1 and TA2. 2, 3 Furthermore, the assays did not show a significant difference of the CRE pathway activity between the two TA4 alleles G and A. The polymorphism leading to a conservative amino-acid exchange in the sixth transmembrane domain of TA4 does not alter the receptor activity in the assays described, and it does not promote constitutive activity as described for mutations in other diseases.
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Although these data do not provide evidence for an altered receptor activity of this TA4 polymorphism, an involvement in BPAD cannot be excluded based on our in vitro data. The polymorphism could influence other signal-transduction pathways of endogenous TA4 or influence ligand binding and thereby modulate the TA4 activity in humans. 1 Some studies have found that grey matter loss correlates negatively with age, 2 raising the possibility that deficits are associated with illness progression. This evidence is supported by a recent prospective imaging study, which found greater temporal and cerebellar grey matter reductions over time in people with bipolar disorder compared to controls, which was correlated with the number of intervening illness episodes. 3 The mechanism that leads to temporal grey matter reduction is, however, unclear. Post mortem evidence of gliosis and cell death is lacking for affective psychosis, 4 suggesting that deficits may be due to reduced neuropil or dendritic arborization. Brain derived neurotrophic factor (BDNF) is associated with multiple cell actions such as cytoskeletal remodelling and neurite outgrowth that could account for these grey matter reductions. 5 This possibility is further supported by an association between reduced hippocampal volume and BDNF genotype in healthy subjects. 6 A frequent, nonconservative single nucleotide polymorphism in the human BDNF gene (dbSNP number rs6265) produces a valine to methionine amino acid substitution at codon 66 (Val 66 Met). The met allele is associated with poorer episodic memory, abnormal hippocampal activation, and neurons transfected with met-BDNF-GFP showed lower depolarization-induced secretion. 7 Whether the BDNF Val 66 Met variant is associated with progressive temporal grey matter reductions and illness progression is not known.
This study sought to test the hypothesis that the individuals with the BDNF met variant would show greater temporal grey matter reductions and have
